Details of issuance or disposal
Report on the Exercise Status of the Fifth Series of Share Acquisition Rights through Third-Party Allotment
1,220,000 shares
The lower thin line represents the existing number of shares to which these shares will be added.
¥1,464,000,000
| Item | Details |
|---|---|
| Type of issuance or disposal | Report on the Exercise Status of the Fifth Series of Share Acquisition Rights through Third-Party Allotment |
| Number of shares to be issued or disposed of | 1,220,000 shares |
| Issue price and disposal price | ¥1,200 per share (exercise price) |
| Total issue value | ¥1,464,000,000 |
| Amount of funds to be raised | Total payment amount: ¥1,464 million; estimated net proceeds after expenses: Not disclosed |
| Specific use of funds | Details Funds for investment in domestically listed securities / Amount ¥364 million paid in connection with the exercise this time, funds to be raised through the future exercise of the unexercised balance of these share acquisition rights and the Sixth and Seventh Series of Share Acquisition Rights / Scheduled timing of expenditures Not disclosed |
| Payment date | 19 November 2026 |
| Intended allottee | EVO FUND (12,200 rights, 1,220,000 shares) |
| Exercise price | ¥1,200 per share; adjustment provisions and floor: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 20,000 rights; unexercised balance after the period subject to the transaction: 7,800 rights |
| Most recent equity financing | 18 November 2026: Issuance of the Fifth Series of Share Acquisition Rights through third-party allotment (issue price and total amount: Not disclosed), 9 November 2026: Issuance of the Fifth, Sixth and Seventh Series of Share Acquisition Rights through third-party allotment and issuance of the First Series of Unsecured Convertible Bonds (detailed amounts: Not disclosed) |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently under review. The Company believes this will contribute to increasing corporate value over the medium to long term as the value investment business progresses. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The receivable relating to payment of the exercise price of the share acquisition rights was set off against the redemption claim on the bonds, thereby fully repaying the bonds. The remaining funds raised will be allocated to investments in listed securities in Japan, with investments to be made in issues trading below their intrinsic value.